CITATION REPORT List of articles citing

Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfu

DOI: 10.1073/pnas.1006965107 Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 18202-7.

Source: https://exaly.com/paper-pdf/49063211/citation-report.pdf

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
122	Possibilities to increase the effectiveness of doxorubicin in cancer cells killing. 2011 , 43, 540-57		49
121	The role of reactive oxygen species in WP 631-induced death of human ovarian cancer cells: a comparison with the effect of doxorubicin. 2011 , 25, 1712-20		29
120	Baicalein protects against doxorubicin-induced cardiotoxicity by attenuation of mitochondrial oxidant injury and JNK activation. 2011 , 112, 2873-81		61
119	Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. 2011 , 71, 3029-41		139
118	Evidence for Pleiotropic Effects of Phosphodiesterase-5 (PDE5) Inhibitors: Emerging Concepts in Cancer and Cardiovascular Medicine. 2011 , 108, 1040-1041		2
117	Roles of sildenafil in enhancing drug sensitivity in cancer. 2011 , 71, 3735-8		52
116	Molecular mechanisms of pharmaceutical drug binding into calsequestrin. <i>International Journal of Molecular Sciences</i> , 2012 , 13, 14326-43	6.3	6
115	Quantitative study of focused ultrasound enhanced doxorubicin delivery to prostate tumor in vivo with MRI guidance. 2012 , 39, 2780-6		12
114	The metallophosphodiesterase Mpped2 impairs tumorigenesis in neuroblastoma. 2012 , 11, 569-81		24
113	OrganicIhorganic nanovesicles for doxorubicin storage and release. 2012 , 8, 5756		23
112	Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. 2012 , 52, 1213-25		840
111	Synergistic cytotoxic action of cisplatin and withaferin A on ovarian cancer cell lines. 2012 , 423, 819-25		43
110	Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection. 2012 , 59, 1921-7		58
109	Sildenafil stimulates the expression of gaseous monoxide-generating enzymes in vascular smooth muscle cells via distinct signaling pathways. 2012 , 84, 1045-54		19
108	Anti-inflammatory and cardioprotective effects of tadalafil in diabetic mice. 2012, 7, e45243		65
107	New insights into chronic inflammation-induced immunosuppression. 2012 , 22, 307-18		145
106	PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Cassette C10) transporter. 2012 , 103, 1531-7		34

105	Potential therapeutic applications of phosphodiesterase inhibition in prostate cancer. 2013, 31, 325-30	28
104	FGF-2 and FGF-16 protect isolated perfused mouse hearts from acute doxorubicin-induced contractile dysfunction. 2013 , 13, 244-53	20
103	Gambogic acid sensitizes ovarian cancer cells to doxorubicin through ROS-mediated apoptosis. 2013 , 67, 199-206	40
102	A2B adenosine receptor blockade inhibits growth of prostate cancer cells. 2013 , 9, 271-80	76
101	Molecular pharmacology of ABCG2 and its role in chemoresistance. 2013 , 84, 655-69	152
100	Sildenafil ameliorates biomarkers of genotoxicity in an experimental model of spontaneous atherosclerosis. 2013 , 12, 128	22
99	Phosphodiesterase-5 inhibitor tadalafil attenuates oxidative stress and protects against myocardial ischemia/reperfusion injury in type 2 diabetic mice. 2013 , 60, 80-8	62
98	Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo. 2013 , 49, 2059-64	14
97	Cardiac expression of human type 2 iodothyronine deiodinase increases glucose metabolism and protects against doxorubicin-induced cardiac dysfunction in male mice. 2013 , 154, 3937-46	17
96	Increasing cGMP-dependent protein kinase I activity attenuates cisplatin-induced kidney injury through protection of mitochondria function. 2013 , 305, F881-90	30
95	Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants. 2013 , 4, 82	13
94	Doxorubicin combined with celecoxib inhibits tumor growth of medullary thyroid carcinoma in xenografted mice. 2014 , 7, 2053-2058	11
93	PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells. 2014 , 15, 758-67	41
92	Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study. 2014 , 174, 964-70	87
91	Pro-apoptotic activity of new analog of anthracyclinesWP 631 in advanced ovarian cancer cell line. 2014 , 28, 273-81	11
90	Co-delivery of Sildenafil (Viagra([])) and Crizotinib for synergistic and improved anti-tumoral therapy. 2014 , 31, 2516-28	28
89	Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells. 2014 , 85, 408-19	56
88	Combinatorial delivery of Crizotinib-Palbociclib-Sildenafil using TPGS-PLA micelles for improved cancer treatment. 2014 , 88, 718-29	45

87	Regulation of OSU-03012 toxicity by ER stress proteins and ER stress-inducing drugs. 2014 , 13, 2384-98	37
86	The role of ABC transporters in ovarian cancer progression and chemoresistance. 2015 , 96, 220-56	104
85	Phosphodiesterase Type 5 as a Candidate Therapeutic Target in Cancers. 2015 , 3, 193-201	7
84	Nexavar/Stivarga and viagra interact to kill tumor cells. 2015 , 230, 2281-98	37
83	Gambogic acid sensitizes resistant breast cancer cells to doxorubicin through inhibiting P-glycoprotein and suppressing survivin expression. 2015 , 235, 76-84	57
82	Hybrid biomaterial based on porous silica nanoparticles and Pluronic F-127 for sustained release of sildenafil: in vivo study on prostate cancer. 2015 , 5, 81348-81355	4
81	PDE5 inhibitors enhance celecoxib killing in multiple tumor types. 2015 , 230, 1115-27	36
80	PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. 2015 , 147, 12-21	144
79	New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is). 2016 , 23, 1239-49	27
78	Sildenafil potentiates the antitumor activity of cisplatin by induction of apoptosis and inhibition of proliferation and angiogenesis. 2016 , 10, 3661-3672	24
77	A Novel Agent Enhances the Chemotherapeutic Efficacy of Doxorubicin in MCF-7 Breast Cancer Cells. 2016 , 7, 249	14
76	Sildenafil (Viagra) sensitizes prostate cancer cells to doxorubicin-mediated apoptosis through CD95. 2016 , 7, 4399-413	29
75	Phosphodiesterase 5 Inhibition Limits Doxorubicin-induced Heart Failure by Attenuating Protein Kinase G I Dxidation. 2016 , 291, 17427-36	34
74	A small molecule nanodrug consisting of amphiphilic targeting ligand-chemotherapy drug conjugate for targeted cancer therapy. 2016 , 230, 34-44	99
73	The Role of PDE5 Inhibitors and the NO/cGMP Pathway in Cancer. 2016 , 4, 74-84	26
72	The Association between Phosphodiesterase Type 5 Inhibitors and Prostate Cancer: Results from the REDUCE Study. 2016 , 196, 715-20	9
71	Beet root juice protects against doxorubicin toxicity in cardiomyocytes while enhancing apoptosis in breast cancer cells. 2016 , 421, 89-101	19
70	Doxorubicin Conjugated to Immunomodulatory Anticancer Lactoferrin Displays Improved Cytotoxicity Overcoming Prostate Cancer Chemo resistance and Inhibits Tumour Development in TRAMP Mice. 2016 , 6, 32062	26

69	Non-Sexual Implications of Phosphodiesterase Type 5 Inhibitors. 2017 , 5, 170-199	11
68	Long-acting PDE5 inhibitor tadalafil prevents early doxorubicin-induced left ventricle diastolic dysfunction in juvenile mice: potential role of cytoskeletal proteins. 2017 , 95, 295-304	7
67	Potential synergistic effect of phosphodiesterase inhibitors with chemotherapy in lung cancer. 2017 , 8, 3648-3656	28
66	A Triphenylphosphonium-Functionalized Mitochondriotropic Nanocarrier for Efficient Co-Delivery of Doxorubicin and Chloroquine and Enhanced Antineoplastic Activity. 2017 , 10,	16
65	Phosphodiesterase type 5 and cancers: progress and challenges. 2017 , 8, 99179-99202	28
64	New NO- and H2S-releasing doxorubicins as targeted therapy against chemoresistance in castration-resistant prostate cancer: in vitro and in vivo evaluations. 2018 , 36, 985-998	19
63	Phosphodiesterase-5 inhibition reduces postoperative metastatic disease by targeting surgery-induced myeloid derived suppressor cell-dependent inhibition of Natural Killer cell cytotoxicity. 2018 , 7, e1431082	48
62	Sildenafil citrate improves the delivery and anticancer activity of doxorubicin formulations in a mouse model of breast cancer. 2018 , 26, 610-615	29
61	The anti-inflammatory and anti-fibrotic effects of tadalafil in thioacetamide-induced liver fibrosis in rats. 2018 , 96, 1308-1317	20
60	Repurposing drugs in oncology (ReDO)-selective PDE5 inhibitors as anti-cancer agents. 2018 , 12, 824	24
59	Association between phosphodiesterase type 5 inhibitors and prostate cancer: A systematic review. 2018 , 28, 560-566	3
58	Randomized study of doxorubicin-based chemotherapy regimens, with and without sildenafil, with analysis of intermediate cardiac markers. 2018 , 4,	9
57	Fabrication of novel combinatorial drug encapsulated micelles for enhanced tumor targeting in intestinal cancer in mouse model. 2019 , 234, 15450	
56	Crosstalk Between Prostate Cancer Stem Cells and Immune Cells: Implications for Tumor Progression and Resistance to Immunotherapy. 2019 , 173-221	1
55	Cancer Stem Cell Resistance to Targeted Therapy. 2019 ,	1
54	LncRNA LOXL1-AS1/miR-let-7a-5p/EGFR-related pathway regulates the doxorubicin resistance of prostate cancer DU-145 cells. 2019 , 71, 1537-1551	31
53	Arginyl-glycyl-aspartic acid (RGD) containing nanostructured lipid carrier co-loaded with doxorubicin and sildenafil citrate enhanced anti-cancer effects and overcomes drug resistance. 2019 , 84, 172-179	12
52	PDE5 Inhibition Stimulates Tie2-Expressing Monocytes and Angiopoietin-1 Restoring Angiogenic Homeostasis in Diabetes. 2019 , 104, 2623-2636	8

51	Remote Ischemic Pre-Conditioning Attenuates Adverse Cardiac Remodeling and Mortality Following Doxorubicin Administration in Mice. 2019 , 1, 221-234	6
50	Phosphodiesterase Type 5 (PDE5) Inhibitors Sensitize Topoisomerase II Inhibitors in Killing Prostate Cancer Through PDE5-Independent Impairment of HR and NHEJ DNA Repair Systems. 2018 , 8, 681	11
49	Q817G mutation in phosphodiesterase type 5: Conformational analysis and dissociation profile of the inhibitor Tadalafil. 2019 , 93, 419-429	6
48	A novel agent attenuates cardiotoxicity and improves antitumor activity of doxorubicin in breast cancer cells. 2019 , 120, 5913-5922	9
47	Levosimendan prevents doxorubicin-induced cardiotoxicity in time- and dose-dependent manner: implications for inotropy. 2020 , 116, 576-591	21
46	Sildenafil Potentiates the Therapeutic Efficacy of Docetaxel in Advanced Prostate Cancer by Stimulating NO-cGMP Signaling. 2020 , 26, 5720-5734	15
45	Cardiovascular risks and toxicity - The Achilles heel of androgen deprivation therapy in prostate cancer patients. 2020 , 1874, 188383	9
44	Osteocrin attenuates inflammation, oxidative stress, apoptosis, and cardiac dysfunction in doxorubicin-induced cardiotoxicity. 2020 , 10, e124	59
43	A dual PI3 kinase/mTOR inhibitor BEZ235 reverses doxorubicin resistance in ABCB1 overexpressing ovarian and pancreatic cancer cell lines. 2020 , 1864, 129556	2
42	Enhanced nanoparticle accumulation by tumor-acidity-activatable release of sildenafil to induce vasodilation. 2020 , 8, 3052-3062	10
41	Sildenafil beyond erectile dysfunction and pulmonary arterial hypertension: Thinking about new indications. 2021 , 35, 235-259	7
40	Repurposing of Phosphodiesterase-5 Inhibitors as Therapeutic Agents Against Human Gastric Cancer.	
39	New Approaches in Oncology for Repositioning Drugs: The Case of PDE5 Inhibitor Sildenafil. 2021 , 11, 627229	7
38	Repurposing of sildenafil as antitumour; induction of cyclic guanosine monophosphate/protein kinase G pathway, caspase-dependent apoptosis and pivotal reduction of Nuclear factor kappa light chain enhancer of activated B cells in lung cancer. 2021 , 73, 1080-1091	1
37	Sildenafil 4.0-Integrated Synthetic Chemistry, Formulation and Analytical Strategies Effecting Immense Therapeutic and Societal Impact in the Fourth Industrial Era. 2021 , 14,	5
36	Sildenafil in Combination Therapy against Cancer: A Literature Review. 2021 , 28, 2248-2259	3
35	The sGC-cGMP Signaling Pathway as a Potential Therapeutic Target in Doxorubicin-Induced Heart Failure: A Narrative Review. 2021 , 1	2
34	The Potential Role of Sildenafil in Cancer Management through EPR Augmentation. 2021, 11,	5

(2015-2021)

33	Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management. <i>Biomedicine and Pharmacotherapy</i> , 2021 , 139, 111708	7.5	45
32	The development of multi-kinase inhibitors as pancreatic cancer therapeutics. 2021 , 32, 779-785		1
31	Role of phosphodiesterase 1 in the pathophysiology of diseases and potential therapeutic opportunities. 2021 , 226, 107858		2
30	Tadalafil enhances the therapeutic efficacy of BET inhibitors in hepatocellular carcinoma through activating Hippo pathway. 2021 , 1867, 166267		2
29	Withaferin A synergizes the therapeutic effect of doxorubicin through ROS-mediated autophagy in ovarian cancer. 2012 , 7, e42265		78
28	Attenuation of doxorubicin-induced cardiotoxicity by mdivi-1: a mitochondrial division/mitophagy inhibitor. 2013 , 8, e77713		73
27	PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide. 2017 , 8, 1449-1468		37
26	PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib]. 2017 , 8, 13464-13475		9
25	New drugs are not enough-drug repositioning in oncology: An update. 2020 , 56, 651-684		22
24	Sildenafil Enhances the Anticancer Activity of Paclitaxel in an ABCB1-Mediated Multidrug Resistance Xenograft Mouse Model. <i>Journal of Cancer Research Updates</i> , 2014 , 3, 169-173	1	1
23	The Possible Chemosensitizing Effect of Different Doses of Indol-3-Carbinol on Transplantable Tumor Model Treated with Doxorubicin. 4, 61-72		
22	Sildenafil Induces Cell Cycle Arrest and Apoptosis in Human Colorectal Cancer HT-29 Cells. <i>Journal of Cancer Research Updates</i> , 2018 , 7, 59-63	1	O
21	Non-classical effects of sildenafil in clinical medicine: an interdisciplinary approach. <i>Meditsinskiy Sovet</i> , 2019 , 192-202	0.4	
20	Activation of the cGMP/protein kinase G system in breast cancer by the dopamine receptor-1 <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2019 , 2, 933-947	4.5	O
19	Pyrophen Isolated from the Endophytic Fungus Strain KARSV04 Synergizes the Effect of Doxorubicin in Killing MCF7 but not T47D Cells. <i>Turkish Journal of Pharmaceutical Sciences</i> , 2020 , 17, 280-284	1.1	
18	First molecular modelling report on tri-substituted pyrazolines as phosphodiesterase 5 (PDE5) inhibitors through classical and machine learning based multi-QSAR analysis. <i>SAR and QSAR in Environmental Research</i> , 2021 , 32, 917-939	3.5	1
17	Cardiac systolic dysfunction in doxorubicin-challenged rats is associated with upregulation of MuRF2 and MuRF3 E3 ligases. <i>Experimental and Clinical Cardiology</i> , 2012 , 17, 101-9		5
16	Sildenafil inhibits the growth of human colorectal cancer in vitro and in vivo. <i>American Journal of Cancer Research</i> , 2015 , 5, 3311-24	4.4	33

15	Caffeic acid phenethyl ester protects against doxorubicin-induced cardiotoxicity and increases chemotherapeutic efficacy by regulating the unfolded protein response <i>Food and Chemical Toxicology</i> , 2021 , 159, 112770	4.7	0
14	How do phosphodiesterase-5 inhibitors affect cancer? A focus on glioblastoma multiforme <i>Pharmacological Reports</i> , 2022 , 1	3.9	О
13	Peristrophe bicalyculata (Retz) Nees contains principles that are cytotoxic to cancer cells and induce caspase-mediated, intrinsic apoptotic death through oxidative stress, mitochondrial depolarisation and DNA damage <i>Biomedicine and Pharmacotherapy</i> , 2022 , 147, 112597	7.5	1
12	Cardiomyocyte Atrophy, an Underestimated Contributor in Doxorubicin-Induced Cardiotoxicity <i>Frontiers in Cardiovascular Medicine</i> , 2022 , 9, 812578	5.4	2
11	Pros and Cons of Pharmacological Manipulation of cGMP-PDEs in the Prevention and Treatment of Breast Cancer <i>International Journal of Molecular Sciences</i> , 2021 , 23,	6.3	1
10	Sildenafil aggravates adriamycin-induced testicular toxicity in rats; a preliminary investigation <i>Drug and Chemical Toxicology</i> , 2021 , 1-7	2.3	
9	Presentation_1.PPTX. 2019 ,		
8	Phosphodiesterase 5 inhibitor sildenafil potentiates the antitumor activity of cisplatin by ROS-mediated apoptosis: a role of deregulated glucose metabolism. <i>Apoptosis: an International Journal on Programmed Cell Death</i> ,	5.4	1
7	Combination therapy of doxorubicin and Sildenafil inhibits the growth of pediatric rhabdomyosarcoma. <i>Journal of Cancer Research and Clinical Oncology</i> ,	4.9	1
6	Design, synthesis and chemoinformatic studies of new thiazolopyrimidine derivatives as potent anticancer agents via phosphodiesterase-5 inhibition and apoptotic inducing activity. 2023 , 1272, 1342	16	2
5	Beyond Erectile Dysfunction: cGMP-Specific Phosphodiesterase 5 Inhibitors for Other Clinical Disorders. 2023 , 63,		1
4	In Vitro Drug Repurposing: Focus on Vasodilators. 2023 , 12, 671		O
3	Nitric Oxide-cGMP-PKG Signaling in the Cardioprotective Effects of Phosphodiesterase 5 Inhibitors. 2023 , 111-126		0
2	Androgen-deprivation therapy with leuprolide increases abdominal adiposity without causing cardiac dysfunction in middle-aged male mice: effect of sildenafil. 2023 , 324, R589-R600		1
1	Immunomodulatory, apoptotic and anti-proliferative potentials of sildenafil in Ehrlich ascites carcinoma murine model: In vivo and in silico insights. 2023 , 119, 110135		O